Neosante Health Solutions’ new lactase supplement soothes colic
Neosante Health Solutions will be making Delictase Oral Drops, a lactase enzyme supplement used to battle baby colic, available to patrons of Amazon.com.
“Getting Delictase on the world’s biggest retailer will help prevent sleepless nights for countless babies and their parents,” João Santos, Neosante CEO, said. “We stand by being the best colic remedy and know Amazon will help people around the world find us as we continue to branch out. Parents need to know a product exists that treats their baby’s crying and improves their overall health by treating the cause, not the symptoms.
Delictase Oral Drops prevent excessive crying and discomfort for babies suffering from colic, a common issue most likely caused by gastrointestinal discomfort, including intestinal cramping. Colic affects up to 40% of children, the Boca Raton, Fla.-based company reported, typically occurring when a child is between 6 weeks and 6 months old.
“Delictase provides just enough lactase to infants to treat colic. It helps babies who may have hypolactasia, but is not intended for severe lactose intolerance,” Santos said. “Lactase is used to digest lactose, preventing fermentation in the body that leads to tummy pains. Lactose also makes the baby’s gut more acidic, which causes diarrhea and really foul diapers.”
Delictase Oral Drops come in a 15-milliliter solution, prepackaged in a dropper, and should be added to breast milk or baby formula. Neosante is a well-known company overseas, having sold more than two million vials of Delictase Oral Drops in 2017.
Neosante Health Solutions is a privately owned Portuguese pharmaceutical company established in 2007 that produces food supplements, medical devices and cosmetics. Neosante currently distributes products to 20 countries on three continents, and is bringing its Delictase Oral Drops to parents in the United States.
Olika marries form and design into new hand sanitizing spray
Olika on Tuesday introduced Minnie a bird-shaped, natural hand sanitizing spray that contains 30 mL of aloe vera and essential oils.
“It’s incredibly exciting to expand the Olika family with the launch of Minnie,” Jessica Postiglione, CEO Olika, said. “Minnie is a natural follow-up to our first product Birdie, and answers the market desire for a second-generation product. Informed by customer feedback, Minnie by Olika may be little, but she is fierce and believes herself superior to her big brother, Birdie.”
Standing at 2.25 x 2 inches and complete with a locking mechanism, Minnie is ergonomically designed to fit in a hand and contains more than 525 sprays. The formulation improves skin hydration for up to 24 hours, the company noted.
Minnie’s fragrance is a blend of aloe vera leaf juice and the essential oils of bergamot, lemon and spearmint.
Minnie is the sister product of Olika’s Birdie, the bird-shaped 2-in-1 hand sanitizer containing a spray and dry wipes, which launched in 2017.
The newest hand sanitizer from the New York-based Olika retails online at $6.49 and is debuting at select Urban Outfitters locations. Minnie is available in robin’s egg, charcoal, eggshell and the latest color, thistle.
FDA rules active in MiraLax can only be marketed as OTC
The Food and Drug Administration earlier this month effectively eliminated any Rx-only competition to Bayer’s OTC laxative MiraLax (polyethylene glycol 3350).
The active ingredient in MiraLax had been approved for sale without a prescription nearly 12 years ago, but since that time, some manufacturers of products containing the identical ingredient for the same use, refused to withdraw their Rx-labeled products from the market and to re-apply for OTC status, as is required under the Federal Food, Drug, and Cosmetic Act.
“Consumers today are more empowered than ever to take their health into their own hands with an increasing array of choice and access to safe and effective over-the-counter medicines. The order confirms the same ingredient, absent a meaningful difference (such as the use or strength), may not be prescription and OTC at the same time,” the Consumer Healthcare Products Association stated in a release issued earlier this week. “This week’s FDA action resolves any remaining questions on this matter and reminds manufacturers to respect the formal procedures underpinning the Rx-to-OTC switch process and to work cooperatively to honor these regulations to prevent consumer confusion in the marketplace.”
The ruling may drive more consumers in search of the OTC laxative to the retail pharmacy. For the 52 weeks ended Nov. 5, 2017, sales of MiraLax across total U.S. multi-outlets totaled $205.2 million, up 3.3%.
FDA’s decision impacts five manufacturers with PEG 3350 ANDA approvals, including Kremers Urban Pharmaceuticals, Breckenridge Pharmaceutical, Nexgen Pharma, Paddock Laboratories and Teva Pharmaceutical.